• Patent-pending oral insulin technology (US Provisional and International PCT Application filed), with the potential to replace daily injections and improve the quality of life of over 9 million type 1 diabetics and the broader needs of over half a billion people with diabetes globally.
   

• Advanced delivery technology ensures efficient insulin delivery and avoids loss to saliva and gastrointestinal degradation, a major barrier to other oral insulin efforts.
   

• Accelerated commercialization pathway from leveraging safe and known FDA-approved drugs in a new dosage form, with Phase I and II clinical trials slated for 2024 and 2025.
   

• Sustainable supply chain without need for refrigeration and needles, as well as less plastic waste, resulting in reduced carbon footprint and environmental impact.
   

• Increased accessibility for insulin due to simplified supply chain, with greater affordability and broader reach especially in lower income geographies.

​

• To meet the needs of millions diabetics by 2025, Insu will scale and expand by venturing into other peptide drugs and setting up the first insulin manufacturing facility in Canada, where insulin was invented.